Participated · Series A · Jul 2026

Lydian has developed PIVOT™, a full‑stack, modular production platform that integrates proprietary reactors, catalysts, process design, software, and balance‑of‑plant into factory‑built modules for synthetic aviation fuel. The platform is designed to cut project capital costs by more than 50% versus competing technologies, operate flexibly with intermittent renewable electricity, and reduce lifecycle greenhouse gas emissions by up to 95%. Lydian produces ASTM‑approved, drop‑in sustainable aviation fuel from captured CO2 and hydrogen and is positioning PIVOT to enable faster, lower‑cost deployment of synthetic fuel projects. The company operates a tonne‑scale pilot plant at its Boston R&D Center of Excellence and plans a commercial demonstration facility targeted for 2028 with first full‑scale commercial deployment expected in 2030. Financially, the company completed a $43 million Series A to support commercialization and deployment activities.

Participated · Series A · Jun 2026

MAKO develops Flightfilm, a shark-skin-inspired surface technology intended to reduce skin-friction drag on aircraft and thereby lower fuel burn and emissions. The company was previously known as MicroTau and is based in Australia. Its immediate plans following the Series A are to pursue certification, scale production and roll out Flightfilm commercially for in-service aircraft. MAKO raised AU$28 million (about US$20 million) in the Series A led by Virescent Ventures to fund those efforts. The article did not disclose revenue, user numbers, or other operating metrics. No further details on product deployment timelines or prior funding were provided.

Participated · Seed · Oct 2025

Founded in 2022 in Tel Aviv, Israel, Asterix Foods builds plant cell culture systems designed to overcome the high capital costs and scalability bottlenecks of traditional precision fermentation. Its compact, low-CAPEX bioreactors operate at room temperature, cut energy and water use, and can run multiple production lines to manufacture diverse bioactive proteins year-round with minimal downtime. Because the units are modular and resource-light, facilities can be deployed on non-arable land and co-located with manufacturing hubs to reduce logistics costs and emissions. The company currently runs a pilot facility in central Tel Aviv that showcases this flexible approach. A multidisciplinary team of eight Ph.D.-level researchers in biotechnology and engineering leads product development. With fresh capital, Asterix plans to expand the pilot plant and start sending product samples to select customers, moving toward commercial-scale production.

Participated · Seed · Sep 2024

Endolith is a Denver-based biotechnology startup combining artificial intelligence with engineered microbial consortia to biologically dissolve metal-bearing minerals and convert them into recoverable solutions. Its software platform identifies and optimizes microbe cocktails that can liberate copper, cobalt and other strategic metals from low-grade or otherwise challenging deposits, offering a potentially lower-cost and more environmentally friendly alternative to conventional mining. Management positions the technology as a strategic resource solution for U.S. mineral security amid rising demand from electric vehicles and AI-driven data centers. Although still at an early stage, the company plans to channel fresh capital into pilot-scale engineering, process validation and the design of its first modular extraction units in partnership with industrial players. Endolith also intends to adhere to strict verification protocols to quantify efficiency, purity and economic viability of recovered metals. To accelerate commercialization, the team is pursuing additional industry collaborations and expects a follow-on tranche once certain technical milestones are met. The recent seed financing brings total capital raised to at least US$13.5 million, giving the company runway to advance toward initial commercial pilots.

Led · Equity · Jun 2023

Edinburgh-headquartered Rhizocore Technologies develops and supplies carefully selected, locally adapted mycorrhizal fungi—in pellet form—to accelerate tree establishment and boost survival rates across diverse environments, including clear-felled forests, former agricultural land, moorlands, reclaimed mining sites and high-altitude terrain. Operating on more than 100 active field sites, the biotech company’s “data-driven, nature-first” approach taps into fungi’s below-ground fertilisation capabilities to deliver measurable growth enhancements for forestry customers. The technology has attracted customers such as Forestry and Land Scotland and The Grosvenor Estate, two of whom also became investors in the latest round. Rhizocore plans to use its proprietary fungi solutions to unlock large-scale restoration and improve the economic returns of land assets by enhancing soil biology. With fresh capital, the firm will scale production capacity at its Roslin facility and expand into North America, where 1.4 billion trees are planted each year. The company’s growing multi-year order book across the UK and Europe underlines early commercial traction, although specific revenue or user figures were not disclosed.